De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
De-epitoping alpha gliadin through targeted amino acid substitutions and mutations addresses the challenge of gluten exposure in celiac disease by reducing immune response while preserving gluten's functional properties.
Patent Information
- Application Number
- US17/624600
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- Priority Date
- 2019-07-04
- Filing Date
- 2020-07-02
- Publication Date
- 2026-02-17
- Estimated Expiration
- 2042-09-16
AI Technical Summary
Celiac disease patients face challenges in adhering to a strict gluten-free diet due to inadvertent exposure, leading to persistent abnormalities and non-responsive disease, highlighting the need for alternative dietary therapies that are accessible and cost-effective.
De-epitoping alpha gliadin by substituting specific amino acid residues at positions 1, 4, and 5, and mutating residues between 57 and 89, generating a de-epitoped alpha gliadin that reduces binding affinity to MHC class DQ2 or DQ8, thereby minimizing immune response.
The de-epitoped alpha gliadin exhibits reduced activation of celiac patient T-cells, maintaining gluten's functional properties while minimizing immune reaction, thus providing a potential dietary management for celiac disease.